# DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure

> **NCT05359835** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Gadolinium Deposition Disease

## Interventions

- **DRUG:** Calcium DTPA and Zinc DTPA

## Key facts

- **NCT ID:** NCT05359835
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-04-11
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Could not recruit subjects quickly enough
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359835, "DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05359835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*